News Search Results
Feb 09, 2026, 21:00 ET MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease
TAINAN, Feb. 9, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer's
More news about: Merry Life Biomedical Company, Ltd.
Feb 09, 2026, 17:31 ET Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight
affecting immunocompromised populations, together contributing around 50% of the total burden.Several leading pharmaceutical and biotechnology companies including Glaxosmithkline, SCYNEXIS, Basilea Pharmaceutica, Shionogi, F2G, Pulmocide, Mycovia Pharmaceuticals, Matinas BioPharma, Biosergen,
More news about: DelveInsight Business Research, LLP
Feb 09, 2026, 16:15 ET Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline
More news about: Nektar Therapeutics
Feb 09, 2026, 16:05 ET REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
which has been shown to correlate with neurocognitive manifestations of the disorder.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Feb 09, 2026, 14:18 ET DOE Partners with RTI International to Administer Newly Launched Genesis Mission Consortium Via TechWerx
energy innovation, discovery science and national security by applying its capabilities to major national challenges—from advanced manufacturing and biotechnology to materials science, nuclear energy, quantum information science and semiconductors."Our role is to provide structured partnerships between
More news about: RTI International
Feb 09, 2026, 09:47 ET Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
has acquired all outstanding shares of Arthrosi's common stock and common stock equivalents.Arthrosi Therapeutics is a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882),
More news about: Swedish Orphan Biovitrum AB
Feb 09, 2026, 09:20 ET NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has
More news about: NeuroSense
Feb 09, 2026, 09:15 ET Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data
BioworksLunai Bioworks (NASDAQ: LNAI) is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biotechnology. Leveraging advanced machine learning and proprietary phenotypic and neurotoxicity datasets, Lunai is redefining how artificial intelligence can
More news about: Lunai Bioworks Inc.
Feb 09, 2026, 09:07 ET Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol
More news about: Innocan Pharma Corporation
Feb 09, 2026, 09:07 ET Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol
More news about: Innocan Pharma Corporation
Feb 09, 2026, 09:00 ET Architecting the Intelligent Lab of the Future: Abio Technologies Launches Abio Spark and Blaze at SLAS2026
scientists innovate. We design AI-first, automation-native solutions that serve as the backbone for global challenges in health, sustainability, and biotechnology.Media Contact: Prem Mohanty ([email protected]).
More news about: Abio Technologies Inc.
Feb 09, 2026, 09:00 ET Human Longevity, Inc. Welcomes Nobel Laureate Michael Levitt to Scientific Advisory Board
major diseases that impact longevity and healthspan."About Human Longevity, Inc.Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, artificial intelligence, and multimodal diagnostics to extend human healthspan. Through its flagship
More news about: Human Longevity, Inc.
Feb 09, 2026, 09:00 ET Architecting the Intelligent Lab of the Future: Abio Technologies Launches Abio Spark and Blaze at SLAS2026
scientists innovate. We design AI-first, automation-native solutions that serve as the backbone for global challenges in health, sustainability, and biotechnology.Media Contact Prem Mohanty [email protected]
More news about: Abio Technologies Inc.
Feb 09, 2026, 08:18 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
/PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA medicines for neurological diseases. This brings Aerska's total funds raised to-date
More news about: EQT
Feb 09, 2026, 08:16 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
/PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA medicines for neurological diseases. This brings Aerska's total funds raised to-date
More news about: EQT
Feb 09, 2026, 08:00 ET Activation Capital Expands Frontier BioHealth and Strengthens Its Continuum of Support for Life Sciences Founders
activation.capital/programs/frontierbiohealth.About Virginia Biotechnology Research Partnership AuthorityThe Virginia Biotechnology Research Partnership Authority ("Authority") is a political subdivision of the Commonwealth of Virginia created
More news about: Activation Capital
Feb 09, 2026, 08:00 ET Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today provided an update on patient outcomes observed in its ongoing Phase 1 ovarian
More news about: Anixa Biosciences, Inc.
Feb 09, 2026, 08:00 ET DIFF Biotech's Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway
community-level immunity.About DIFF BiotechZhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) is a clinical-stage biotechnology company specializing in its proprietary Viraltech Architect Platform. Leveraging this platform, the company has built an integrated, end-to-end
More news about: DIFF Biotech
Feb 09, 2026, 08:00 ET 'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Feb 09, 2026, 08:00 ET Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board
Bar-Ilan University and a leading expert in multiscale molecular modeling. His research integrates quantum mechanics, artificial intelligence, and biotechnology to accelerate drug discovery, ag-chemical development, and materials design. Prof. Major is a pioneer in hybrid QM/MM simulations and the developer
More news about: Evogene
Feb 09, 2026, 07:00 ET Lilly to acquire Orna Therapeutics to advance cell therapies
Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.Orna
More news about: Eli Lilly and Company
Feb 09, 2026, 06:55 ET Global Personal Care Ingredients Market Expands from US$22.5 billion in 2026 to US$32.3 Billion by 2033, Says Persistence Market Research
antimicrobial, and sensory-enhancing properties are gaining preference among manufacturers seeking cost efficiency and simplified formulations. Advances in biotechnology, green chemistry, and enzyme-based processing are enabling the development of next-generation ingredients that deliver superior performance while
More news about: Persistence Market Research Pvt. Ltd.
Feb 09, 2026, 05:37 ET 'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Feb 06, 2026, 12:51 ET Tampa General's Innovation Week Returns with New Programming to Showcase Breakthroughs in Patient Care and Technology
care—where innovation converges with world‑class clinical care, exceptional academics, cutting‑edge medical research, and leading life sciences and biotechnology companies," said John Couris, president and CEO of Florida Health Sciences Center | Tampa General Hospital. "Tampa General is proud to host TGH
More news about: Tampa General Hospital
Feb 06, 2026, 08:57 ET CaseBioscience® Launches CaseCryo® CTG DMSO and CaseStor® HSS at ATW 2026, Advancing Next-Generation Biopreservation for Cell Therapy
http://www.casebioscience.com, United StatesAbout CaseBioscienceCaseBioscience is a research-driven biotechnology company developing high-quality biopreservation and culture solutions that advance cell therapy and reproductive medicine. The company's science
More news about: CaseBioscience Inc.